Considering that variants in FTO showed high correlation with body weight and also interact with dopamine signaling in the brain, a clinical trial was designed to develop a genotype-specific and individualized therapy approach for obesity targeting FTO (rs8050136) variant (NCT03525002). This evidence concerns the gene FTO and obesity disorder.